{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T10:29:29Z","timestamp":1765189769398,"version":"3.46.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"DOI":"10.1186\/s12348-025-00558-7","type":"journal-article","created":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T10:24:39Z","timestamp":1765189479000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term outcomes of intravitreal 0.19\u00a0mg fluocinolone acetonide implant in uveitic macular edema after prior local corticosteroid treatments"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3592-2820","authenticated-orcid":false,"given":"Ana Margarida","family":"Ferreira","sequence":"first","affiliation":[]},{"given":"Marta In\u00eas","family":"Silva","sequence":"additional","affiliation":[]},{"given":"S\u00f3nia","family":"Torres-Costa","sequence":"additional","affiliation":[]},{"given":"Cl\u00e1udia","family":"Oliveira-Ferreira","sequence":"additional","affiliation":[]},{"given":"Ana Catarina","family":"Pedrosa","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds","family":"Figueira","sequence":"additional","affiliation":[]},{"given":"Joana Rodrigues","family":"Ara\u00fajo","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"558_CR1","doi-asserted-by":"publisher","unstructured":"Jabbour M, Kodjikian L, Bourdin A, Rougier MB, Serrar Y, Weber M, et al (2024) Efficacity and safety of the Fluocinolone acetonide implant in uveitic macular edema: a real-life study from the French uveitis network. J Pers Med 14(3). https:\/\/doi.org\/10.3390\/jpm14030245","DOI":"10.3390\/jpm14030245"},{"issue":"1","key":"558_CR2","doi-asserted-by":"publisher","first-page":"2352019","DOI":"10.1080\/07853890.2024.2352019","volume":"56","author":"YC Chang","year":"2024","unstructured":"Chang YC, Kao TE, Chen CL, Lin YC, Hwang DK, Hwang YS et al (2024) Use of corticosteroids in non-infectious uveitis: expert consensus in Taiwan. Ann Med 56(1):2352019. https:\/\/doi.org\/10.1080\/07853890.2024.2352019","journal-title":"Ann Med"},{"issue":"8","key":"558_CR3","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s40265-020-01314-y","volume":"80","author":"LM Valdes","year":"2020","unstructured":"Valdes LM, Sobrin L (2020) Uveitis therapy: the corticosteroid options. Drugs 80(8):765\u2013773. https:\/\/doi.org\/10.1007\/s40265-020-01314-y","journal-title":"Drugs"},{"key":"558_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/164_2016_98","volume":"237","author":"IM Adcock","year":"2017","unstructured":"Adcock IM, Mumby S (2017) Glucocorticoids. Handb Exp Pharmacol 237:171\u2013196. https:\/\/doi.org\/10.1007\/164_2016_98","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"558_CR5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2165\/00002018-200225010-00004","volume":"25","author":"CN McGhee","year":"2002","unstructured":"McGhee CN, Dean S, Danesh-Meyer H (2002) Locally administered ocular corticosteroids: benefits and risks. Drug Saf 25(1):33\u201355. https:\/\/doi.org\/10.2165\/00002018-200225010-00004","journal-title":"Drug Saf"},{"issue":"1","key":"558_CR6","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s40123-016-0052-8","volume":"5","author":"FJ Go\u00f1i","year":"2016","unstructured":"Go\u00f1i FJ, Stalmans I, Denis P, Nordmann JP, Taylor S, Diestelhorst M et al (2016) Elevated intraocular pressure after intravitreal steroid injection in diabetic macular edema: monitoring and management. Ophthalmol Ther 5(1):47\u201361. https:\/\/doi.org\/10.1007\/s40123-016-0052-8","journal-title":"Ophthalmol Ther"},{"key":"558_CR7","doi-asserted-by":"publisher","first-page":"1402396","DOI":"10.3389\/fmed.2024.1402396","volume":"11","author":"T Zhang","year":"2024","unstructured":"Zhang T, Liu Z, Li N (2024) The application of dexamethasone implants in uveitis treatment. Front Med 11:1402396","journal-title":"Front Med"},{"issue":"1","key":"558_CR8","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12348-023-00360-3","volume":"13","author":"RB Gupta","year":"2023","unstructured":"Gupta RB, Ilin J, Gottlieb CC (2023) Efficacy of intravitreal dexamethasone implant used as monotherapy for the treatment of macular edema in non-infectious uveitis: a retrospective analysis. J Ophthalmic Inflamm Infect 13(1):42","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"558_CR9","unstructured":"Zeng S, Liu X-L (2023) A review of ten years of experience using dexamethasone intravitreal implants (Ozurdex) for uveitis. Eur Rev Med Pharmacol Sci 27(5)"},{"issue":"3","key":"558_CR10","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1097\/IAE.0000000000002901","volume":"41","author":"T Mathis","year":"2021","unstructured":"Mathis T, Cerquaglia A, Weber M, Guillarme-Sallit R, Malcl\u00e8s A, Voirin N et al (2021) Uveitis treated with dexamethasone implant. Retina 41(3):620\u2013629","journal-title":"Retina"},{"issue":"5","key":"558_CR11","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1007\/s00417-021-05504-6","volume":"260","author":"A Studsgaard","year":"2022","unstructured":"Studsgaard A, Clemmensen K\u00d8, Nielsen MS (2022) Intravitreal Fluocinolone acetonide 0.19\u00a0mg (Iluvien\u00ae) for the treatment of uveitic macular edema: 2-year follow-up of 20 patients. Graefes Arch Clin Exp Ophthalmol 260(5):1633\u20131639. https:\/\/doi.org\/10.1007\/s00417-021-05504-6","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"1","key":"558_CR12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12348-019-0168-9","volume":"9","author":"LF Weber","year":"2019","unstructured":"Weber LF, Marx S, Auffarth GU, Scheuerle AF, Tandogan T, Mayer C et al (2019) Injectable 0.19-mg Fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema. J Ophthalmic Inflamm Infect 9(1):3. https:\/\/doi.org\/10.1186\/s12348-019-0168-9","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"2","key":"558_CR13","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/s0002-9394(14)74235-7","volume":"103","author":"E Bloch-Michel","year":"1987","unstructured":"Bloch-Michel E, Nussenblatt RB (1987) International uveitis study group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol 103(2):234\u2013235. https:\/\/doi.org\/10.1016\/s0002-9394(14)74235-7","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"558_CR14","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ajo.2005.03.057","volume":"140","author":"SUNW Group","year":"2005","unstructured":"Group SUNW (2005) Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol 140(3):509\u2013516","journal-title":"Am J Ophthalmol"},{"issue":"8","key":"558_CR15","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1016\/j.ophtha.2006.03.027","volume":"113","author":"CW Lardenoye","year":"2006","unstructured":"Lardenoye CW, van Kooij B, Rothova A (2006) Impact of macular edema on visual acuity in uveitis. Ophthalmology 113(8):1446\u20131449. https:\/\/doi.org\/10.1016\/j.ophtha.2006.03.027","journal-title":"Ophthalmology"},{"issue":"4","key":"558_CR16","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/bjo.80.4.332","volume":"80","author":"A Rothova","year":"1996","unstructured":"Rothova A, Suttorp-van Schulten M, Treffers WF, Kijlstra A (1996) Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol 80(4):332\u2013336. https:\/\/doi.org\/10.1136\/bjo.80.4.332","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"558_CR17","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ajo.2011.02.009","volume":"152","author":"HA Leder","year":"2011","unstructured":"Leder HA, Jabs DA, Galor A, Dunn JP, Thorne JE (2011) Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis. Am J Ophthalmol 152(3):441\u2013448e2. https:\/\/doi.org\/10.1016\/j.ajo.2011.02.009","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"558_CR18","doi-asserted-by":"publisher","first-page":"690","DOI":"10.3109\/09273948.2016.1160130","volume":"25","author":"AC Tsang","year":"2017","unstructured":"Tsang AC, Virgili G, Abtahi M, Gottlieb CC (2017) Intravitreal dexamethasone implant for the treatment of macular edema in chronic non-infectious uveitis. Ocul Immunol Inflamm 25(5):690\u2013697. https:\/\/doi.org\/10.3109\/09273948.2016.1160130","journal-title":"Ocul Immunol Inflamm"},{"key":"558_CR19","doi-asserted-by":"publisher","first-page":"961","DOI":"10.2147\/DDDT.S403259","volume":"17","author":"Y Mushtaq","year":"2023","unstructured":"Mushtaq Y, Mushtaq MM, Gatzioufas Z, Ripa M, Motta L, Panos GD (2023) Intravitreal Fluocinolone acetonide implant (ILUVIEN\u00ae) for the treatment of retinal conditions: a review of clinical studies. Drug Des Devel Ther 17:961\u2013975. https:\/\/doi.org\/10.2147\/DDDT.S403259","journal-title":"Drug Des Devel Ther"},{"issue":"7","key":"558_CR20","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/IAE.0b013e31827e247b","volume":"33","author":"A Ad\u00e1n","year":"2013","unstructured":"Ad\u00e1n A, Pelegr\u00edn L, Rey A, Lloren\u00e7 V, Mesquida M, Molins B et al (2013) Dexamethasone intravitreal implant for treatment of uveitic persistent cystoid macular edema in vitrectomized patients. Retina 33(7):1435\u20131440. https:\/\/doi.org\/10.1097\/IAE.0b013e31827e247b","journal-title":"Retina"},{"key":"558_CR21","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2147\/OPTH.S80500","volume":"9","author":"WC Lam","year":"2015","unstructured":"Lam WC, Albiani DA, Yoganathan P, Chen JC, Kherani A, Maberley DA et al (2015) Real-world assessment of intravitreal dexamethasone implant (0.7\u00a0mg) in patients with macular edema: the CHROME study. Clin Ophthalmol 9:1255\u20131268. https:\/\/doi.org\/10.2147\/OPTH.S80500","journal-title":"Clin Ophthalmol"},{"issue":"3","key":"558_CR22","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.ophtha.2009.11.027","volume":"117","author":"C Pavesio","year":"2010","unstructured":"Pavesio C, Zierhut M, Bairi K, Comstock TL, Usner DW (2010) Evaluation of an intravitreal Fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 117(3):567\u2013575e1. https:\/\/doi.org\/10.1016\/j.ophtha.2009.11.027","journal-title":"Ophthalmology"},{"issue":"6","key":"558_CR23","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/s41433-021-01608-9","volume":"36","author":"C Pavesio","year":"2022","unstructured":"Pavesio C, Heinz C (2022) Non-infectious uveitis affecting the posterior segment treated with Fluocinolone acetonide intravitreal implant: 3-year fellow eye analysis. Eye 36(6):1231\u20131237","journal-title":"Eye"},{"issue":"9","key":"558_CR24","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1001\/archopht.126.9.1191","volume":"126","author":"DG Callanan","year":"2008","unstructured":"Callanan DG, Jaffe GJ, Martin DF, Pearson PA, Comstock TL (2008) Treatment of posterior uveitis with a Fluocinolone acetonide implant. Arch Ophthalmol 126(9):1191\u20131201. https:\/\/doi.org\/10.1001\/archopht.126.9.1191","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"558_CR25","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12348-020-00225-z","volume":"10","author":"B Bodaghi","year":"2020","unstructured":"Bodaghi B, Nguyen QD, Jaffe G, Khoramnia R, Pavesio C (2020) Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye\u2013evaluating the 0.2 \u00b5g\/day Fluocinolone acetonide intravitreal implant (ILUVIEN\u00ae). J Ophthalmic Inflamm Infect 10(1):32","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"3","key":"558_CR26","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1007\/s40123-022-00504-z","volume":"11","author":"S Lebrize","year":"2022","unstructured":"Lebrize S, Arnould L, Bourredjem A, Busch C, Rehak M, Massin P et al (2022) Intraocular pressure changes after intravitreal Fluocinolone acetonide implant: results from four European countries. Ophthalmol Ther 11(3):1217\u20131229. https:\/\/doi.org\/10.1007\/s40123-022-00504-z","journal-title":"Ophthalmol Ther"},{"issue":"2","key":"558_CR27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/IJG.0b013e31802d696f","volume":"16","author":"K Iwao","year":"2007","unstructured":"Iwao K, Inatani M, Kawaji T, Koga T, Mawatari Y, Tanihara H (2007) Frequency and risk factors for intraocular pressure elevation after posterior sub-Tenon capsule triamcinolone acetonide injection. J Glaucoma 16(2):251\u2013256. https:\/\/doi.org\/10.1097\/IJG.0b013e31802d696f","journal-title":"J Glaucoma"},{"issue":"1","key":"558_CR28","doi-asserted-by":"publisher","first-page":"13248","DOI":"10.1038\/s41598-020-70269-7","volume":"10","author":"VA de Vries","year":"2020","unstructured":"de Vries VA, Bassil FL, Ramdas WD (2020) The effects of intravitreal injections on intraocular pressure and retinal nerve fiber layer: a systematic review and meta-analysis. Sci Rep 10(1):13248. https:\/\/doi.org\/10.1038\/s41598-020-70269-7","journal-title":"Sci Rep"},{"issue":"6","key":"558_CR29","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/j.ajo.2005.01.022","volume":"139","author":"O \u00c7eki\u00e7","year":"2005","unstructured":"\u00c7eki\u00e7 O, Chang S, Tseng JJ, Akar Y, Barile GR, Schiff WM (2005) Cataract progression after intravitreal triamcinolone injection. Am J Ophthalmol 139(6):993\u2013998. https:\/\/doi.org\/10.1016\/j.ajo.2005.01.022","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"558_CR30","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/sj.eye.6702802","volume":"22","author":"Y Chu","year":"2008","unstructured":"Chu Y, Chung E, Kwon O, Lee J, Koh H (2008) Objective evaluation of cataract progression associated with a high dose intravitreal triamcinolone injection. Eye 22(7):895\u2013899. https:\/\/doi.org\/10.1038\/sj.eye.6702802","journal-title":"Eye"},{"issue":"11","key":"558_CR31","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1007\/s10792-023-02828-6","volume":"43","author":"A Moll-Udina","year":"2023","unstructured":"Moll-Udina A, Hernanz I, Sainz-de-la-Maza M, Pelegr\u00edn L, Coelho-Borges AI, Pazos M et al (2023) Intravitreal Fluocinolone acetonide 0.19\u00a0mg (ILUVIEN\u00ae) in patients with non-infectious uveitis: real-world effectiveness and safety outcomes at 12 months. Int Ophthalmol 43(11):4181\u20134195","journal-title":"Int Ophthalmol"},{"issue":"1","key":"558_CR32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12348-024-00409-x","volume":"14","author":"I Kozak","year":"2024","unstructured":"Kozak I, Gurbaxani A, Pandova M (2024) The effectiveness of the 0.19\u00a0mg Fluocinolone acetonide implant in treating non-infectious posterior uveitis: a real-world experience. J Ophthalmic Inflamm Infect 14(1):24","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"2","key":"558_CR33","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s40135-017-0134-3","volume":"5","author":"JR de Oliveira Dias","year":"2017","unstructured":"de Oliveira Dias JR, Nunes RP, Goldhardt R (2017) New drugs and new posterior delivery methods in CME. Curr Ophthalmol Rep 5(2):160\u2013168","journal-title":"Curr Ophthalmol Rep"},{"issue":"6","key":"558_CR34","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3109\/09273948.2015.1070180","volume":"23","author":"BM Burkholder","year":"2015","unstructured":"Burkholder BM, Moradi A, Thorne JE, Dunn JP (2015) The dexamethasone intravitreal implant for noninfectious uveitis: practice patterns among uveitis specialists. Ocul Immunol Inflamm 23(6):444\u2013453. https:\/\/doi.org\/10.3109\/09273948.2015.1070180","journal-title":"Ocul Immunol Inflamm"}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-025-00558-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12348-025-00558-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-025-00558-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T10:24:41Z","timestamp":1765189481000},"score":1,"resource":{"primary":{"URL":"https:\/\/joii-journal.springeropen.com\/articles\/10.1186\/s12348-025-00558-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["558"],"URL":"https:\/\/doi.org\/10.1186\/s12348-025-00558-7","relation":{},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"10 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the Institutional Ethic Committee of Local Health Unit of S\u00e3o Jo\u00e3o, Porto, Portugal (CES \u2013 Comiss\u00e3o de \u00c9tica para a Sa\u00fade) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards\u201d. This article was redacted according to the recommendations of The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Due to the characteristics of this study, informed consent was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}